Tarsus Pharmaceuticals (TARS) News Today $46.52 -0.40 (-0.85%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Grant GrossMendelsohn LLC Has $2.18 Million Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Grant GrossMendelsohn LLC lessened its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 26.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 39,299 shares of the company's stock after selling 14,331 shares during the quarter.January 18 at 6:11 AM | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Buy" by BrokeragesJanuary 18 at 3:12 AM | americanbankingnews.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Recommendation of "Buy" from BrokeragesShares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) have received a consensus recommendation of "Buy" from the six analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, four have assigned a buy recoJanuary 18 at 3:11 AM | marketbeat.comTarsus Pharmaceuticals: Strong Market Penetration and Promising Expansion into Ocular RosaceaJanuary 16 at 9:27 AM | markets.businessinsider.comTarsus Pharmaceuticals (TARS) Receives a Buy from BarclaysJanuary 16 at 9:27 AM | markets.businessinsider.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Purchased by Assenagon Asset Management S.A.Assenagon Asset Management S.A. increased its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 0.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,146,812 shares of tJanuary 16 at 5:03 AM | marketbeat.comTarsus Pharmaceuticals provides 2025 updateJanuary 14, 2025 | markets.businessinsider.comOppenheimer Sticks to Its Buy Rating for Tarsus Pharmaceuticals (TARS)January 14, 2025 | markets.businessinsider.comTarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Down 6.3% - Here's What HappenedTarsus Pharmaceuticals (NASDAQ:TARS) Shares Down 6.3% - Should You Sell?January 14, 2025 | marketbeat.comTarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye CareJanuary 13, 2025 | markets.businessinsider.comTarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Down - What's Next?Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Down - Should You Sell?January 13, 2025 | marketbeat.comTarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye CareJanuary 13, 2025 | globenewswire.comJPMorgan Chase & Co. Has $14.48 Million Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)JPMorgan Chase & Co. grew its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 2,088.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 440,167 shares of the company's stock after acquirJanuary 11, 2025 | marketbeat.comTarsus Pharmaceutical - Eye Care TherapeuticsJanuary 2, 2025 | msn.comTarsus Pharmaceuticals (NASDAQ:TARS) Sets New 1-Year High - Here's What HappenedTarsus Pharmaceuticals (NASDAQ:TARS) Hits New 52-Week High - Still a Buy?December 30, 2024 | marketbeat.comGeode Capital Management LLC Increases Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Geode Capital Management LLC boosted its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 8.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 835,790 shares of the company's stock after buying an additional 6December 27, 2024 | marketbeat.comThe Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDexDecember 26, 2024 | finance.yahoo.comHow Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit RunDecember 26, 2024 | yahoo.comBarclays PLC Grows Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Barclays PLC boosted its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 345.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 98,663 shares of the company's stock after purcDecember 24, 2024 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Buy" by BrokeragesTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) has received an average recommendation of "Buy" from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, five have given a buy recommendation aDecember 24, 2024 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Position Lessened by State Street CorpState Street Corp lowered its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 2.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 899,379 shares of the company's stocDecember 22, 2024 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Agilent (A) and Teva Pharmaceutical (TEVA)December 18, 2024 | markets.businessinsider.comTarsus Pharmaceuticals (NASDAQ:TARS) Sets New 12-Month High - Still a Buy?Tarsus Pharmaceuticals (NASDAQ:TARS) Sets New 1-Year High - Here's What HappenedDecember 18, 2024 | marketbeat.comWellington Management Group LLP Has $4.78 Million Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Wellington Management Group LLP increased its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 14.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 145,347 shares of the coDecember 17, 2024 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by Lord Abbett & CO. LLCLord Abbett & CO. LLC lifted its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 28.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 594,876 shares of the company's stock afterDecember 16, 2024 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Down - Should You Sell?Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Down - What's Next?December 13, 2024 | marketbeat.comTarsus Pharmaceuticals: Early Rollout Exceeding ExpectationsDecember 10, 2024 | seekingalpha.com23,199 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Bought by Verition Fund Management LLCVerition Fund Management LLC bought a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 23,199 shares of the company's stock, valued at approDecember 10, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Boosts Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Charles Schwab Investment Management Inc. boosted its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 10.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 29December 10, 2024 | marketbeat.comVestal Point Capital LP Buys Shares of 230,000 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Vestal Point Capital LP purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 230,000 shares of the companyNovember 29, 2024 | marketbeat.comHealthcare of Ontario Pension Plan Trust Fund Sells 51,200 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Healthcare of Ontario Pension Plan Trust Fund reduced its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 13.1% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 338,400 shares of the company'sNovember 29, 2024 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Recommendation of "Buy" from AnalystsTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) has been assigned an average recommendation of "Buy" from the seven research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, five have assigned a buyNovember 29, 2024 | marketbeat.com321,898 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Acquired by Ally Bridge Group NY LLCAlly Bridge Group NY LLC bought a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 321,898 shares of the company's stock, valued at approximaNovember 28, 2024 | marketbeat.comTarsus Pharmaceuticals' SWOT analysis: XDEMVY success drives stock outlookNovember 27, 2024 | uk.investing.comConnor Clark & Lunn Investment Management Ltd. Reduces Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Connor Clark & Lunn Investment Management Ltd. lowered its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 44.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investNovember 27, 2024 | marketbeat.comFinding Winners In Biotech, Probably The Riskiest SectorNovember 26, 2024 | seekingalpha.comMutual of America Capital Management LLC Invests $4.29 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Mutual of America Capital Management LLC acquired a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 130,454 shares of the company's stock, valuNovember 22, 2024 | marketbeat.comJennison Associates LLC Boosts Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Jennison Associates LLC lifted its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 47.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,178,580 shares of the companyNovember 21, 2024 | marketbeat.comTarsus PharmaceuticalsNovember 19, 2024 | forbes.comGSA Capital Partners LLP Invests $740,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)GSA Capital Partners LLP acquired a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 22,493 shares of the company's stockNovember 18, 2024 | marketbeat.comFY2024 EPS Estimates for TARS Increased by Lifesci CapitalTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Analysts at Lifesci Capital raised their FY2024 earnings per share estimates for Tarsus Pharmaceuticals in a report released on Thursday, November 14th. Lifesci Capital analyst C. Jubinville now expects that the company will post earningsNovember 18, 2024 | marketbeat.comWilliam Blair Has Optimistic Outlook of TARS FY2024 EarningsTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Investment analysts at William Blair increased their FY2024 earnings estimates for Tarsus Pharmaceuticals in a report issued on Thursday, November 14th. William Blair analyst L. Hanbury-Brown now expects that the company will earn ($3.26)November 18, 2024 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2024 Earnings Call TranscriptNovember 16, 2024 | msn.comTarsus Pharmaceuticals Third Quarter 2024 Earnings: Beats ExpectationsNovember 16, 2024 | finance.yahoo.comTarsus Pharmaceuticals (NASDAQ:TARS) Trading Down 5.3% - Here's WhyTarsus Pharmaceuticals (NASDAQ:TARS) Trading Down 5.3% - What's Next?November 15, 2024 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Given New $41.00 Price Target at The Goldman Sachs GroupThe Goldman Sachs Group raised their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a "neutral" rating in a research report on Friday.November 15, 2024 | marketbeat.comTarsus Pharmaceuticals price target raised to $73 from $61 at H.C. WainwrightNovember 15, 2024 | markets.businessinsider.comTarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business AchievementsNovember 14, 2024 | finanznachrichten.deTarsus Pharmaceuticals Reports Strong Q3 2024 PerformanceNovember 14, 2024 | markets.businessinsider.comTarsus Pharmaceuticals (NASDAQ:TARS) Hits New 52-Week High on Analyst UpgradeTarsus Pharmaceuticals (NASDAQ:TARS) Sets New 1-Year High After Analyst UpgradeNovember 14, 2024 | marketbeat.com Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address TARS Media Mentions By Week TARS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TARS News Sentiment▼0.750.64▲Average Medical News Sentiment TARS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TARS Articles This Week▼104▲TARS Articles Average Week Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Revolution Medicines News Lantheus News Blueprint Medicines News BridgeBio Pharma News Legend Biotech News Elanco Animal Health News Cytokinetics News Nuvalent News Grifols News Viking Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TARS) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TARS Stock Alerts